机构：[1]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.[2]Department of Nephrology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.[3]Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, China.[4]Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou, China. zyq973@hotmail.com.[5]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China. wanglei_voice@yahoo.com.
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|2 区生物
小类|2 区细胞生物学
最新[2025]版：
大类|1 区生物学
小类|2 区细胞生物学
第一作者：
第一作者机构：[1]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.[2]Department of Nephrology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
推荐引用方式(GB/T 7714)：
Chen Zhida,Wu Chunying,Liu Yuting,et al.Correction: ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway.[J].Cell death & disease.2020,11(10):905.doi:10.1038/s41419-020-02933-9.
APA：
Chen Zhida,Wu Chunying,Liu Yuting,Li Haonan,Zhu Yeyan...&Wang Lei.(2020).Correction: ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway..Cell death & disease,11,(10)
MLA：
Chen Zhida,et al."Correction: ELABELA attenuates deoxycorticosterone acetate/salt-induced hypertension and renal injury by inhibition of NADPH oxidase/ROS/NLRP3 inflammasome pathway.".Cell death & disease 11..10(2020):905
生物学